Non-Pharmacological Interventions for Depression and Anxiety in Parkinson’s Disease

Journal of Parkinson s Disease, Год журнала: 2024, Номер 14(s1), С. S135 - S146

Опубликована: Апрель 9, 2024

Non-pharmacological interventions, including cognitive-behavioral therapy (CBT), non-invasive brain stimulation (NIBS), electroconvulsive (ECT), light (LT), and physical rehabilitation/exercise, have shown promise as effective approaches to treat symptoms of depression anxiety in individuals with Parkinson's disease (PD). In this narrative literature overview, we discuss the state-of-the-art regarding these treatment options address future perspectives for clinical practice research. interventions hold PD. There is meta-analytic evidence efficacy CBT, NIBS, ECT, LT, exercise on improving depressive symptoms. For symptoms, CBT shows large effects but scientific other non-pharmacological limited. Importantly, treatments are safe no or mild side-effects. More research needed tailor individuals' needs combined may provide synergistic effects.We conclude that should be considered alternative augmentative pharmacological neurosurgical

Язык: Английский

---

Prevalence and associations of self‐reported sleep problems in a large sample of patients with Parkinson's disease

Journal of Sleep Research, Год журнала: 2025, Номер unknown

Опубликована: Янв. 19, 2025

Summary Sleep problems are important comorbid features of, and risk factors for, neurodegenerative diseases such as Parkinson's disease (PD). To assess the prevalence associations of sleep in patients with PD we analysed data from almost 54,000 participants Fox Insight study, including 38,588 PD. common PD, ~84% respondents reporting difficulty falling or staying asleep. Experiences insomnia, restless leg syndrome, vivid dreams, acting out use medication over‐represented compared matched healthy controls. Male sex onset before age 50 were also associated a greater problems. A physician diagnosis insomnia was more symptoms depression, impairment cognition‐dependent independence, lower quality life. higher OFF periods without 6.7% endorsed complaints their most bothersome symptom, reported non‐specific poor problem. These had better life depression cognitive impairments than for whom postural instability indicating relative burden is contextualised by severity motor symptoms. Overall, these findings reinforce high very large sample patients, indicate daily function

Язык: Английский

---

Chronobiology of Parkinson's disease: Past, present and future

European Journal of Neuroscience, Год журнала: 2022, Номер 57(1), С. 178 - 200

Опубликована: Ноя. 7, 2022

Parkinson's disease is a neurodegenerative disorder predominately affecting midbrain dopaminergic neurons that results in broad range of motor and non-motor symptoms. Sleep complaints are among the most common symptoms, even prodromal period. alterations patients may be associated with dysregulation circadian rhythms, intrinsic 24-h cycles control essential physiological functions, or side effects from levodopa medication physical mental health challenges. The impact on sleep disturbances not fully understood; as such, we review systems, cellular molecular mechanisms underlie perturbations disease. We also discuss potential benefits chronobiology-based personalized medicine management both terms behavioural pharmacological interventions. propose fuller understanding clock function shed important new light aetiology symptomatology allow for improvements quality life millions people

Язык: Английский

---

Melatonin as a Chronobiotic/Cytoprotective Agent in REM Sleep Behavior Disorder

Brain Sciences, Год журнала: 2023, Номер 13(5), С. 797 - 797

Опубликована: Май 13, 2023

Dream-enactment behavior that emerges during episodes of rapid eye movement (REM) sleep without muscle atonia is a parasomnia known as REM disorder (RBD). RBD constitutes prodromal marker α-synucleinopathies and serves one the best biomarkers available to predict diseases such Parkinson disease, multiple system atrophy dementia with Lewy bodies. Most patients showing will convert an α-synucleinopathy about 10 years after diagnosis. The diagnostic advantage relies on prolonged time, its predictive power absence disease-related treatments could act confounders. Therefore, are candidates for neuroprotection trials delay or prevent conversion pathology abnormal α-synuclein metabolism. administration melatonin in doses exhibiting chronobiotic/hypnotic effect (less than mg daily) commonly used first line treatment (together clonazepam) RBD. At higher dose, may also be effective cytoprotector halt progression. However, allometric derived from animal studies (in 100 mg/day range) rarely employed clinically regardless demonstrated toxicity phase 1 pharmacological up normal volunteers. This review discusses application RBD: (a) symptomatic RBD; (b) possible disease-modifying α-synucleinopathies. To what degree has therapeutic efficacy prevention awaits further investigation, particular multicenter double-blind trials.

Язык: Английский

---

Blunted Melatonin Circadian Rhythm in Parkinson’s Disease: Express Bewilderment

Neurotoxicity Research, Год журнала: 2024, Номер 42(5)

Опубликована: Авг. 23, 2024

Язык: Английский

---

Zustandsschwankungen bei der Parkinson-Krankheit jenseits von On‑/Off-Fluktuationen

DGNeurologie, Год журнала: 2024, Номер 7(6), С. 453 - 460

Опубликована: Окт. 8, 2024

---

Fighting Against the Clock: Circadian Disruption and Parkinson’s Disease

Journal of Movement Disorders, Год журнала: 2023, Номер 17(1), С. 1 - 14

Опубликована: Ноя. 21, 2023

Circadian disruption is being increasingly recognized as a critical factor in the development and progression of Parkinson’s disease (PD). This review aims to provide an in-depth overview relationship between circadian PD by exploring molecular, cellular, behavioral aspects this interaction. will include comprehensive understanding how clock gene system transcription–translation feedback loops function they are diminished PD. The article also discusses role genes regulation rhythms, well impact dysregulation on mitochondrial function, oxidative stress, neuroinflammation, including microbiota-gut-brain axis, which have all been proposed crucial mechanisms pathophysiology Finally, highlights potential therapeutic strategies targeting rhythm for treatment

Язык: Английский

---

Ultra‐Small ATP‐Decorated Gold Nanoparticles for Targeting Amyloid Fibrils in Neurodegenerative Diseases

Advanced Functional Materials, Год журнала: 2023, Номер 34(17)

Опубликована: Дек. 22, 2023

Abstract Ultrafine Gold nanoparticles (Au NPs) functionalized with various biomolecules constitute an alternative to antibodies as anti‐amyloidogenic agents. However, generating stable ultrafine Au NPs high surface activity is challenging. Here, the capacity of phosphate groups in used stabilize NPs. The characteristics decorated adenosine mono‐, di‐, and tri‐phosphate are compared well peptide nucleic acid‐containing controls. Among them, ATP‐Au found be superior having small size (2–4 nm) stability (for several months) when analysed by spectroscopy electron microscopy. Spectroscopy analysis also revealed that each ATP‐stabilized NP 7–8 molecules ATP. ThT binding TEM imaging showed efficiently prevented amyloid fibril formation vitro Aβ‐42, α ‐Synuclein Glucosylceramide metabolite, disaggregated their pre‐formed fibrils. NMR interaction safe toward cultured SH‐SY5Y cells co‐incubated amyloids inhibited cytotoxicity readily enter inhibit fibrils within them. results indicates pharmacological potentials ATP

Язык: Английский

---

CHRONOTYPE AND DAILY FUNCTIONING OF PATIENTS WITH DIFFERENT MOTOR SUBTYPES OF PARKINSON DISEASE

The Medical and Ecological Problems, Год журнала: 2024, Номер 28(1), С. 41 - 48

Опубликована: Апрель 30, 2024

Introduction. Sleep and circadian rhythm disturbances can occur at any stage of Parkinson disease (PD) significantly affect quality life. Chronotypes patients with PD are associated different phenotypes, in particular the motor subtype. Thus, we hypothesized that subtypes may have differences distribution chronotypes patterns daily activity. Methods materials. We conducted clinical research on basis Centre for Disease Neurodegenerative Diseases Department Neurological Poltava State Medical University. was verified according to recommendations International Movement Disorders Parkinson's Society. The subtype determined by Stebbin method, which is based calculation Stebbins coefficient sum Unified Rating Scale scores. examined were divided into 3 groups PD: group 1 (n = 38) - predominance postural instability gait disorders (PIGD); 2 26) tremor mixed subtype; control 30) conditionally healthy individuals without CNS lesions. Circadian analyzed using Munich Chronotype Questionnaire (MCTQ). Results. It found sleep onset time getting out bed later (p<0.001 p=0.042, respectively), latency longer (p<0.001), duration shorter (p=0.001), mid-sleep corresponded a (p<0.001). Patients PIGD had (p=0.038), inertia (p=0.028). shown tendency PD, mostly subtype, Light exposure indirectly moderately correlated all study groups. both (p<0.001) level light during day statistically mid-sleep. Conclusion. differ from age-matched controls neurodegenerative diseases chronotype pattern functioning. differences, namely, duration, predisposition chronotype, inertia.

Язык: Английский

---

Sleep quality in patients with Parkinson’s disease in the Republic of Moldova – preliminary results

Romanian Journal of Neurology, Год журнала: 2024, Номер 23(2), С. 133 - 141

Опубликована: Июнь 30, 2024

Background and objectives. The rising prevalence of sleep issues are a consequent societal problem, notably impacting individuals with Parkinson’s disease (PD). This study aims to examine the differences in quality between diagnosed patients their counterparts, while also highlighting its effects on symptoms life. Materials methods. enrolled 37 PD subjects. Sleep quality, established via Pittsburgh Quality Index (PSQI), was compared through case control approach against 49 symptomatology assessment ensured via: Hoehn & Yahr (H&Y); Movement Disorder Society-Unified rating scale (MDS-UPDRS I-IV); Non-motor Symptom Scale (NMSS); Beck Depression Inventory (BDI); Montreal Cognitive Assessment (MoCA); for Outcomes – Psychosocial Functioning (SCOPA-PS); 39-Item Disease Questionnaire (PDQ-39). Results. Compared homologues, subjects were prone worse subjective (18.9% vs. 8.2%), efficiency (13.5% 4.1%), diurnal functionality (27% 12.2%), related breathing disorders (62.2% 46.9%). global PSQI positively correlates H&Y staging (rp= 0.443, p=0.008), UPDRS-III 0.369, p=0.029), UPDRS-IV (rp=0.412, p=0.011). >5 registered higher (p=0.091), BDI (p=0.928), SCOPA-PS (p=0.051). PSQI5 PDQ-39 (rp=0.423, p=0.010) 0.462, p=0.004). Conclusions. proved clear correlation altered patterns clinical presentation delineating worsening motor along non-motor symptoms. In addition, life psychosocial functioning is at risk those manifesting disturbances. Correspondingly, greater interest should be applied establishment prophylactic measures.

Язык: Английский

---